Professor | Qiaojun He | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Qiaojun He
Contact Information	qiaojunhe@zju.edu.cn
Language ability	Chinese, English
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Qiaojun He

Contact Information

qiaojunhe@zju.edu.cn

Language ability

Chinese, English

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Pharmaceutical Sciences
Work Experience	Currently - Zhejiang University - Director of Drug Safety Evaluation Research Center Currently - Zhejiang University - Director of Key Laboratory of Preclinical Study of Anti-tumor Drugs Currently - Zhejiang University - Director of Public Service Platform for Early Druggability Evaluation of Innovative Drugs Currently - Zhejiang University - Vice President of Innovation Institute of Medicine
Awards	Zhejiang Province Pharmaceutical Association Science and Technology Award Second Prize (2017): Research on Anti-tumor Treatment Strategies Based on Retinoic Acid and Its Receptors Ministry of Education Higher Education Scientific Research Outstanding Achievement Award Second Prize (2017): Discovery of Anti-tumor Drug Targets Targeting Tumor Hypoxic Microenvironment Zhejiang Province Natural Science Award Third Prize (2016): Research on Anti-tumor Drug Combination Based on Molecular Targets Zhejiang Province Science and Technology Progress Award Second Prize (2014): Research on Anti-tumor Effects of Retinoic Acid and Its Derivatives Ministry of Education Science and Technology Progress Award Second Prize (2014): Research on Key Technologies and Models for ADMET Drugability Evaluation China Pharmaceutical Association Science and Technology Award Second Prize (2014): Research on Key Technologies and Models for ADMET Drugability Evaluation China Pharmaceutical Association Science and Technology Award Third Prize (2014): Evaluation and Mechanism Research of Anti-tumor Drug Activity Based on Molecular Targets Zhejiang Province Seventh Higher Education Teaching Achievement Award Second Prize (2014): Research on Pharmacy Undergraduate Teaching Reform Aiming at Autonomous Learning and Ability Cultivation Zhejiang Province Science and Technology Progress Award Second Prize (2011): Discovery and Development of New Anti-tumor Drugs Targeting Topoisomerase Zhejiang Province Science and Technology Progress Award Third Prize (2011): Design and Development of Innovative Drugs for Anti-senile Dementia Based on Targets Zhejiang Province Science and Technology Progress Award Second Prize (2010): Design and Discovery of Targeted Anti-tumor Drugs

University/Lab Affiliation and Title

Zhejiang University

Faculty

Pharmaceutical Sciences

Work Experience

Currently - Zhejiang University - Director of Drug Safety Evaluation Research Center
Currently - Zhejiang University - Director of Key Laboratory of Preclinical Study of Anti-tumor Drugs
Currently - Zhejiang University - Director of Public Service Platform for Early Druggability Evaluation of Innovative Drugs
Currently - Zhejiang University - Vice President of Innovation Institute of Medicine

Awards

Zhejiang Province Pharmaceutical Association Science and Technology Award Second Prize (2017): Research on Anti-tumor Treatment Strategies Based on Retinoic Acid and Its Receptors
Ministry of Education Higher Education Scientific Research Outstanding Achievement Award Second Prize (2017): Discovery of Anti-tumor Drug Targets Targeting Tumor Hypoxic Microenvironment
Zhejiang Province Natural Science Award Third Prize (2016): Research on Anti-tumor Drug Combination Based on Molecular Targets
Zhejiang Province Science and Technology Progress Award Second Prize (2014): Research on Anti-tumor Effects of Retinoic Acid and Its Derivatives
Ministry of Education Science and Technology Progress Award Second Prize (2014): Research on Key Technologies and Models for ADMET Drugability Evaluation
China Pharmaceutical Association Science and Technology Award Second Prize (2014): Research on Key Technologies and Models for ADMET Drugability Evaluation
China Pharmaceutical Association Science and Technology Award Third Prize (2014): Evaluation and Mechanism Research of Anti-tumor Drug Activity Based on Molecular Targets
Zhejiang Province Seventh Higher Education Teaching Achievement Award Second Prize (2014): Research on Pharmacy Undergraduate Teaching Reform Aiming at Autonomous Learning and Ability Cultivation
Zhejiang Province Science and Technology Progress Award Second Prize (2011): Discovery and Development of New Anti-tumor Drugs Targeting Topoisomerase
Zhejiang Province Science and Technology Progress Award Third Prize (2011): Design and Development of Innovative Drugs for Anti-senile Dementia Based on Targets
Zhejiang Province Science and Technology Progress Award Second Prize (2010): Design and Discovery of Targeted Anti-tumor Drugs

Areas of Focus	Tumor Pharmacology Drug Toxicology New Drug Development
Publications	Ubiquitin-dependent Degradation of CDK2 Drives the Therapeutic Differentiation of AML by Targeting PRDX2, Ying M, Shao X, Jing H, Liu Y, Qi X, Cao J, Chen Y, Xiang S, Song H, Hu R, Wei G, Yang B, He Q, 2018 Multi-kinase inhibitor CT-707 targets liver cancer by interrupting the hypoxia-activated IGF-1R-YAP axis, Zhu H, Wang D, Yuan T, Yan F, Zeng C, Dai X, Chen Z, Chen Y, Zhou T, Fan G, Ying M, Cao J, Luo P, Liu X, Hu Y, Peng Y, He Q, Yang B, 2018 HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport, Luo P, Xu Z, Li G, Yan H, Zhu Y, Zhu H, Ma S, Yang B, He Q, 2018 AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer, Hong Zhu, Lin-Lin Chang, Fang-Jie Yan, Yan Hu, Chen-Ming Zeng, Tian-Yi Zhou, Tao Yuan, Mei-Dan Ying, Ji Cao, He Q, Yang B, 2018 Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization, Weng Q, Wang J, Wang J, Wang J, Sattar F, Zhang Z, Zheng J, Xu Z, Zhao M, Liu X, Yang L, Hao G, Fang L, Lu QR, Yang B, He Q, 2018 All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages, Qian Zhou, Miao Xian, Senfeng Xiang, Danyan Xiang, Xuejing Shao, Jincheng Wang, Xiaochun Yang, Bo Yang, Meidan Ying, Qiaojun He, 2017 Inhibition of KLF4 by statins reverses Adriamycin-induced metastasis and cancer stemness in osteosarcoma cells, Yangling Li, Miao Xian, Bo Yang, Meidan Ying, Qiaojun He, 2017 Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis, Miao Xian, Handi Cao, Ji Cao, Xuejing Shao, Difeng Zhu, Ning Zhang, Ping Huang, Weixu Li, Bo Yang, Meidan Ying, Qiaojun He, 2017 Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1, Xu L, Zhu Y, Shao J, Chen M, Yan H, Li G, Zhu Y, Xu Z, Yang B, Luo P, He Q, 2017 The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα, Ying M, Zhang L, Zhou Q, Shao X, Cao J, Zhang N, Li W, Zhu H, Yang B, He Q, 2016 All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARalpha-mediated DNA damage, Xu Z, Shao J, Li L, Peng X, Chen M, Li G, Yan H, Yang B, Luo P, He Q, 2016 E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα, Zhang L, Zhou Q, Zhang N, Li W, Ying M, Ding W, Yang B, He Q, 2014 Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α, Cai TY, Liu XW, Zhu H, Cao J, Zhang J, Ding L, Lou JS, He Q, Yang B, 2014 Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway, Li Y, Luo P, Wang J, Dai J, Yang X, Wu H, Yang B, He Q, 2014 Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis, Wu Y, Fu Y, Zheng L, Lin G, Ma J, Lou J, Zhu H, He Q, Yang B, 2014 Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis, Ying M, Zhou X, Zhong L, Lin N, Jing H, Luo P, Yang X, Song H, Yang B, He Q, 2013 Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes, Xue T, Luo P, Zhu H, Zhao Y, Wu H, Gai R, Wu Y, Yang B, Yang X, He Q, 2012 GDC-0941 sensitizes breast cancer to ABT-737 in vitro

Areas of Focus

Tumor Pharmacology
Drug Toxicology
New Drug Development

Publications

Ubiquitin-dependent Degradation of CDK2 Drives the Therapeutic Differentiation of AML by Targeting PRDX2, Ying M, Shao X, Jing H, Liu Y, Qi X, Cao J, Chen Y, Xiang S, Song H, Hu R, Wei G, Yang B, He Q, 2018
Multi-kinase inhibitor CT-707 targets liver cancer by interrupting the hypoxia-activated IGF-1R-YAP axis, Zhu H, Wang D, Yuan T, Yan F, Zeng C, Dai X, Chen Z, Chen Y, Zhou T, Fan G, Ying M, Cao J, Luo P, Liu X, Hu Y, Peng Y, He Q, Yang B, 2018
HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport, Luo P, Xu Z, Li G, Yan H, Zhu Y, Zhu H, Ma S, Yang B, He Q, 2018
AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer, Hong Zhu, Lin-Lin Chang, Fang-Jie Yan, Yan Hu, Chen-Ming Zeng, Tian-Yi Zhou, Tao Yuan, Mei-Dan Ying, Ji Cao, He Q, Yang B, 2018
Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization, Weng Q, Wang J, Wang J, Wang J, Sattar F, Zhang Z, Zheng J, Xu Z, Zhao M, Liu X, Yang L, Hao G, Fang L, Lu QR, Yang B, He Q, 2018
All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages, Qian Zhou, Miao Xian, Senfeng Xiang, Danyan Xiang, Xuejing Shao, Jincheng Wang, Xiaochun Yang, Bo Yang, Meidan Ying, Qiaojun He, 2017
Inhibition of KLF4 by statins reverses Adriamycin-induced metastasis and cancer stemness in osteosarcoma cells, Yangling Li, Miao Xian, Bo Yang, Meidan Ying, Qiaojun He, 2017
Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis, Miao Xian, Handi Cao, Ji Cao, Xuejing Shao, Difeng Zhu, Ning Zhang, Ping Huang, Weixu Li, Bo Yang, Meidan Ying, Qiaojun He, 2017
Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1, Xu L, Zhu Y, Shao J, Chen M, Yan H, Li G, Zhu Y, Xu Z, Yang B, Luo P, He Q, 2017
The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα, Ying M, Zhang L, Zhou Q, Shao X, Cao J, Zhang N, Li W, Zhu H, Yang B, He Q, 2016
All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARalpha-mediated DNA damage, Xu Z, Shao J, Li L, Peng X, Chen M, Li G, Yan H, Yang B, Luo P, He Q, 2016
E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα, Zhang L, Zhou Q, Zhang N, Li W, Ying M, Ding W, Yang B, He Q, 2014
Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α, Cai TY, Liu XW, Zhu H, Cao J, Zhang J, Ding L, Lou JS, He Q, Yang B, 2014
Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway, Li Y, Luo P, Wang J, Dai J, Yang X, Wu H, Yang B, He Q, 2014
Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis, Wu Y, Fu Y, Zheng L, Lin G, Ma J, Lou J, Zhu H, He Q, Yang B, 2014
Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis, Ying M, Zhou X, Zhong L, Lin N, Jing H, Luo P, Yang X, Song H, Yang B, He Q, 2013
Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes, Xue T, Luo P, Zhu H, Zhao Y, Wu H, Gai R, Wu Y, Yang B, Yang X, He Q, 2012
GDC-0941 sensitizes breast cancer to ABT-737 in vitro

Tumor Pharmacology: Differentiation Inducers Osteosarcoma Leukemia Molecular Mechanisms Tumor Cell Interaction Klf4+ Stem Cell Subpopulation Mdm2 Protein Chemotherapy Resistance New Therapeutic Targets Differentiation Therapy Drug Toxicology: Anti-Tumor Drugs Cardiotoxicity Hepatotoxicity Neurotoxicity Autophagy Oxidative Stress Oligodendrocyte Differentiation Hmgb1 P38 Hdac New Drug Development: Drug Safety Evaluation Innovative Drugs Preclinical Pharmacology Toxicology Research Anti-Tumor Drugs Cardiovascular Drugs Metabolic Drugs Immunomodulatory Drugs Clinical Trial Approvals New Drug Certificates

Peihua Luo - Zhejiang University

Zhifei Xu - Zhejiang University

Xuejing Shao - Zhejiang University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us